<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433927</url>
  </required_header>
  <id_info>
    <org_study_id>FIRE-3</org_study_id>
    <nct_id>NCT00433927</nct_id>
  </id_info>
  <brief_title>5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)</brief_title>
  <official_title>Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Volker Heinemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The FIRE-3 trial is a multicenter randomized phase III trial investigating 5-FU, folinic acid
      and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line
      treatment of metastatic colorectal cancer. Planned accrual is 284 evaluable patients per
      treatment arm. The primary study endpoint is objective response rate. Secondary endpoints are
      median progression free survival, median overall survival, safety, and secondary resection
      rate.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>approximate 6 months after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival</measure>
    <time_frame>approximate 6 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>approximate 3 years after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary resection rate with curative intent</measure>
    <time_frame>up to 3 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity (according to NCI-CTCAE)</measure>
    <time_frame>approximate 6 months after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">568</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI plus Cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI plus Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folinic acid</intervention_name>
    <description>Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m² iv, 30 - 90 min day 1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  KRAS-Wildtype status

          -  Histologically confirmed adenocarcinoma of the colon or rectum.

          -  Stage IV disease.

          -  ECOG 0-2.

          -  Patients considered suitable for application of chemotherapy.

          -  Age 18 - 75 years.

          -  In- or outpatient treatment.

          -  Estimated life expectancy &gt; 3 months.

          -  Measurable index lesion according to RECIST criteria. Evaluation of tumor
             manifestations ≤ 2 weeks prior to treatment start.

          -  Effective contraception.

          -  Adequate hematologic function: leukocytes &gt;= 3000/µl, neutrophils &gt;= 1500/µl,
             platelets &gt;= 100.000/µ, and hemoglobin &gt;= 9g/dl.

          -  Bilirubin &lt;= 1,5x upper limit of normal (ULN).

          -  ALAT and ASAT &lt;= 2,5x ULN, in case of liver metastases &lt;= 5x ULN.

          -  Serum creatinine &lt;= 1,5x ULN.

          -  No operations within 4 weeks prior to treatment start. No cytologic biopsies within 1
             week prior to treatment start. Operation sequels need to be completely healed. Major
             operations must not be expected at time of study begin, except for potential secondary
             resection of liver metastases. In case of secondary resection of liver metastases,
             bevacizumab must be discontinued 6-8 weeks prior to surgery.

          -  No relevant toxicities due to prior medical treatment at time of study entry.

        Exclusion Criteria:

          -  KRAS-Mutation of the tumor

          -  Prior treatment directed against the epidermal growth factor receptor (EGFR).

          -  Prior treatment with bevacizumab.

          -  Prior chemotherapy for colorectal cancer, except for adjuvant chemotherapy dating back
             &gt; 6 months prior to study entry.

          -  Experimental medical treatment within 30 days prior to study entry.

          -  Known hypersensitivity reaction to any study medication.

          -  Pregnant or breast feeding women (pregnancy needs to be excluded by testing of
             beta-HCG).

          -  Known or suspected cerebral metastases.

          -  Clinically significant coronary heart disease, myocardial infarction within the last
             12 months or high risk of uncontrolled arrhythmia.

          -  Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhea.

          -  Symptomatic peritoneal carcinosis.

          -  Severe chronic wounds, ulcera or bone fracture.

          -  Uncontrolled hypertension.

          -  Severe proteinuria (nephrotic syndrome).

          -  Arterial thromboembolic events or hemorrhage within 6 months prior to study entry
             (except tumor bleeding surgically treated by tumor resection).

          -  Bleeding diatheses or coagulopathy.

          -  Full dose anticoagulation.

          -  Known DPD-deficiency (special screening not required).

          -  Known glucuronidation-deficiency (special screening not required).

          -  Medical history of other malignant disease within 5 years prior to study entry, except
             for basalioma, and in-situ cervical carcinoma if treated with curative intent.

          -  Known alcohol or drug abuse.

          -  Medical or psychiatric condition which contradicts participation of study.

          -  Limited legal capacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Munich - Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Sponsor Delegated Person</investigator_title>
  </responsible_party>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

